Although no direct clinical interventions targeting IRAK3 currently exist, its potential value in bladder cancer should not be overlooked, and the gene remains a promising candidate for therapeutic development in bladder cancer treatment. This evidence concerns the gene IRAK3 and urinary bladder cancer.